UNIVERSITY OF NEBRASKA MEDICAL CENTER
Integrase Inhibitors during pregnancy and Neurodevelopmental Outcomes: Underlying Mechanism and Therapeutic Intervention
Integrase Inhibitors during pregnancy and Neurodevelopmental Outcomes: Underlying Mechanism and Therapeutic Intervention is a funding opportunity from UNIVERSITY OF NEBRASKA MEDICAL CENTER, up to 567305, closing April 30, 2029.
Apr 30, 2029
(1004d left)Overview
Project Summary Background: Dolutegravir (DTG) is a first-line antiretroviral drug used in combination therapy for the treatment of human immunodeficiency virus type-1 (HIV-1) infection. Due to the roll out of generic DTG-based regimen, its inclusion in national treatment guidelines and rising pretreatment resistance…